Absence of mutations in the HBsAg “a” determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol

Nucleic acid polymers (NAPs) clear HBsAg from the blood by blocking its release from infected hepatocytes of patients with chronic Hepatitis B. In the REP 102 protocol (NCT02646189) monotherapy with the NAP REP 2139 achieved 2 – 7 log reductions of serum HBsAg accompanied by 3 – 9 log reductions in serum HBV DNA and the appearance of anti-HBs.